The medical guidelines for childhood LCH have been published in Pediatric Blood & Cancer  (PBC), Wiley Online Library.

More ...
An­nu­al in­ter­na­tio­nal con­fe­rence of sci­en­tists, pa­tho­lo­gists and cli­ni­ci­ans discussing histiocytoses and their backgrounds. More ...
An International Community of Professionals Dedicated to Research and Treatment More ...
PubMed comprises more than 20 million citations for biomedical literature from MEDLINE, life science journals, and online books. More ...

European Union Clinical Trials Register of the European Medicines Agency

More ...

European Clinical Trials Database of the European Medicines Agency

More ...
Rare diseases in EU
Why do rare diseases need specific EU support? More ...
Euro Histio Net has received funding from the European Union, in the framework of the Public Health Programme. More ...

Follow-up - Required Tests and Frequency

Author(s): Euro Histio Net Work Group for LCH Guidelines (see introduction page), Created: 2011/05/21, last update: 2012/01/23

Tab. 7. Recommendations for follow-up of patients with LCH

Group of Patients



All Patients

Clinical assessment

End of therapy
Every clinc visit


Height, Weight, Pubertal status

End of therapy
Every 6 months until final height is achieved


History of thirst, polyuria

Every clinic visit


Neurological assessment

Every clinic visit

With involvement of bone (axial skeleton and/or limbs)

Orthopaedic assessment

End of therapy
Yearly until completion of pubertal growth

With involvement of ear, mastoid and skull base

Audiometry or Audiometry
Evoked Responses in younger children

End of therapy
Before entering school
If symptoms develop

With involvement of oral tissue and jaw

Dental assessment


CNS positive or with involvement of skull base (orbital lesions, DI, anterior pituitary deficiency)

Neuropsychometric assessment

End of therapy
Every 1 - 2 years


Cerebral MRI
(details see here)

End of therapy

With involvement of lungs


End of therapy
Every 6 months for 2 years
Every year for 10 yerars

With involvement of liver


End of therapy


Bilirubin, γGT, Alkaline phosphatase

End of therapy